Abstract
Dementia, especially Alzheimer’s Disease (AD) and vascular dementia, is a major public health problem that continues to expand in both economically emerging and hegemonic countries. In 2017, the World Alzheimer Report estimated that over 50 million people were living with dementia globally. Metabolic dysfunctions of brain structures such as the hippocampus and cerebral cortex have been implicated as risk factors for dementia. Several well-defined metabolic risk factors for AD include visceral obesity, chronic inflammation, peripheral and brain insulin resistance, type 2 diabetes mellitus (T2DM), hypercholesterolemia, and others. In this review, we describe the relationship between the dysmetabolic mechanisms, although still unknown, and dementia, particularly AD. Adiponectin (ADPN), the most abundant circulating adipocytokine, acts as a protagonist in the metabolic dysfunction associated with AD, with unexpected and intriguing dual biological functions. This contradictory role of ADPN has been termed the adiponectin paradox. Some evidence suggests that the adiponectin paradox is important in amyloidogenic evolvability in AD. We present cumulative evidence showing that AD and T2DM share many common features. We also review the mechanistic pathways involving brain insulin resistance. We discuss the importance of the evolvability of amyloidogenic proteins (APs), defined as the capacity of a system for adaptive evolution. Finally, we describe potential therapeutic strategies in AD, based on the adiponectin paradox.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
Data availability
Not applicable.
Code availability
Not applicable.
References
Ahtiluoto S, Polvikoski T, Peltonen M et al (2010) Diabetes, Alzheimer disease, and vascular dementia: A population-based neuropathologic study. Neurology 75:1195–1202. https://doi.org/10.1212/WNL.0b013e3181f4d7f8
Alzheimer A (1906) Über einen eigenartigen schweren ErkrankungsprozeB der Hirnrinde. Neurologisches Centralblatt 23:1129–1136
Ambros V (2004) The functions of animal microRNAs. Nature 431:350–355. https://doi.org/10.1038/nature02871
Ballard C, Gauthier S, Corbett A et al (2011) Alzheimer’s disease. Lancet 377:1019–1031. https://doi.org/10.1016/S0140-6736(10)61349-9
Barrios-Silva LV, Parnell M, Shinwari ZB, et al. (2018) Activin subfamily peptides predict chronological age in humans. Physiol Rep 6:e13823. https://doi.org/10.14814/phy2.13823
Bartel DP (2004) MicroRNAs Cell 116:281–297. https://doi.org/10.1016/S0092-8674(04)00045-5
Bednarska-Makaruk M, Graban A, Wiśniewska A et al (2017) Association of adiponectin, leptin and resistin with inflammatory markers and obesity in dementia. Biogerontology 18:561–580. https://doi.org/10.1007/s10522-017-9701-0
Bergmark BA, Cannon CP, White WB et al (2017) Baseline adiponectin concentration and clinical outcomes among patients with diabetes and recent acute coronary syndrome in the EXAMINE trial. Diabetes Obes Metab 19:962–969. https://doi.org/10.1111/dom.12905
Borges MC, Lawlor DA, de Oliveira C et al (2016) Role of Adiponectin in Coronary Heart Disease Risk. Circ Res 119:491–499. https://doi.org/10.1161/CIRCRESAHA.116.308716
Boura-Halfon S, Zick Y (2009) Phosphorylation of IRS proteins, insulin action, and insulin resistance. Am J Physiol-Endocrinol Metab 296:E581–E591. https://doi.org/10.1152/ajpendo.90437.2008
Cai H, Cong W, Ji S et al (2012) Metabolic Dysfunction in Alzheimers Disease and Related Neurodegenerative Disorders. Curr Alzheimer Res 9:5–17. https://doi.org/10.2174/156720512799015064
Carrington JC (1979) Ambros V (2003) Role of MicroRNAs in Plant and Animal Development. Science 301:336–338. https://doi.org/10.1126/science.1085242
Cezaretto A, Suemoto CK, Bensenor I et al (2018) Association of adiponectin with cognitive function precedes overt diabetes in the Brazilian Longitudinal Study of Adult Health: ELSA. Diabetol Metab Syndr 10:54. https://doi.org/10.1186/s13098-018-0354-1
Chakrabarti S, Kumar Khemka V, Banerjee A, et al (2015) Metabolic Risk Factors of Sporadic Alzheimer’s Disease: Implications in the Pathology, Pathogenesis and Treatment. Aging Dis 6:282. https://doi.org/10.14336/AD.2014.002
Chari S, Hopkinson CRN, Daume E, Sturm G (1979) PURIFICATION OF “INHIBIN” FROM HUMAN OVARIAN FOLLICULAR FLUID. Acta Endocrinol 90:157–166. https://doi.org/10.1530/acta.0.0900157
Chen C-F, Huang J, Li H et al (2015) MicroRNA-221 regulates endothelial nitric oxide production and inflammatory response by targeting adiponectin receptor 1. Gene 565:246–251. https://doi.org/10.1016/j.gene.2015.04.014
Correia SC, Santos RX, Perry G et al (2011) Insulin-resistant brain state: The culprit in sporadic Alzheimer’s disease? Ageing Res Rev 10:264–273. https://doi.org/10.1016/j.arr.2011.01.001
de Felice FG, Lourenco M V, Ferreira ST (2014) How does brain insulin resistance develop in Alzheimer’s disease? Alzheimer’s Dement 10.https://doi.org/10.1016/j.jalz.2013.12.004
Du H, Fu Z, He G et al (2015) MicroRNA-218 targets adiponectin receptor 2 to regulate adiponectin signaling. Mol Med Rep 11:4701–4705. https://doi.org/10.3892/mmr.2015.3282
Duan H, Zhang X, Song R et al (2020) Upregulation of miR-133a by adiponectin inhibits pyroptosis pathway and rescues acute aortic dissection. Acta Biochim Biophys Sin 52:988–997. https://doi.org/10.1093/abbs/gmaa078
Dukic L, Simundic A-M, Martinic-Popovic I et al (2016) The role of human kallikrein 6, clusterin and adiponectin as potential blood biomarkers of dementia. Clin Biochem 49:213–218. https://doi.org/10.1016/j.clinbiochem.2015.10.014
Erol A (2008) An Integrated and Unifying Hypothesis for the Metabolic Basis of Sporadic Alzheimer’s Disease. J Alzheimer’s Dis 13:241–253. https://doi.org/10.3233/JAD-2008-13302
Fitzpatrick AL, Kuller LH, Ives DG et al (2004) Incidence and Prevalence of Dementia in the Cardiovascular Health Study. J Am Geriatr Soc 52:195–204. https://doi.org/10.1111/j.1532-5415.2004.52058.x
Francischetti EA, Dezonne RS, Pereira CM et al (2020) Insights Into the Controversial Aspects of Adiponectin in Cardiometabolic Disorders. Horm Metab Res 52:695–707. https://doi.org/10.1055/a-1239-4349
Gaddy-Kurten D, Tsuchida K, Vale W (1995) Activins and the Receptor Serine Kinase Superfamily. In: Proceedings of the 1993 Laurentian Hormone Conference. Elsevier, pp 109–129
Gao Q, Yao X, Zheng J (2015) MiR-323 Inhibits Prostate Cancer Vascularization Through Adiponectin Receptor. Cell Physiol Biochem 36:1491–1498. https://doi.org/10.1159/000430313
Haan MN (2006) Therapy Insight: type 2 diabetes mellitus and the risk of late-onset Alzheimer’s disease. Nat Clin Pract Neurol 2:159–166. https://doi.org/10.1038/ncpneuro0124
Hashimoto M, Ho G, Sugama S et al (2021) Possible Role of Activin in the Adiponectin Paradox-Induced Progress of Alzheimer’s Disease. J Alzheimer’s Dis 81:451–458. https://doi.org/10.3233/JAD-210206
Hashimoto M, Ho G, Sugama S et al (2018) Evolvability of Amyloidogenic Proteins in Human Brain. J Alzheimer’s Dis 62:73–83. https://doi.org/10.3233/JAD-170894
Ho G, Takamatsu Y, Wada R, et al (2020) Connecting Alzheimer’s Disease With Diabetes Mellitus Through Amyloidogenic Evolvability. Front Aging Neurosci 12.https://doi.org/10.3389/fnagi.2020.576192
Hoyda TD, Ferguson AV (2010) Adiponectin Modulates Excitability of Rat Paraventricular Nucleus Neurons by Differential Modulation of Potassium Currents. Endocrinology 151:3154–3162. https://doi.org/10.1210/en.2009-1390
Huang C-Y, Chang A-C, Chen H-T et al (2016) Adiponectin promotes VEGF-C-dependent lymphangiogenesis by inhibiting miR-27b through a CaMKII/AMPK/p38 signaling pathway in human chondrosarcoma cells. Clin Sci 130:1523–1533. https://doi.org/10.1042/CS20160117
Hulsmans M, van Dooren E, Mathieu C, Holvoet P (2012) Decrease of miR-146b-5p in Monocytes during Obesity Is Associated with Loss of the Anti-Inflammatory but Not Insulin Signaling Action of Adiponectin. PLoS ONE 7:e32794. https://doi.org/10.1371/journal.pone.0032794
Hwang MS, Yu N, Stinson SY et al (2013) miR-221/222 Targets Adiponectin Receptor 1 to Promote the Epithelial-to-Mesenchymal Transition in Breast Cancer. PLoS ONE 8:e66502. https://doi.org/10.1371/journal.pone.0066502
Ishida M, Shimabukuro M, Yagi S et al (2014) MicroRNA-378 Regulates Adiponectin Expression in Adipose Tissue: A New Plausible Mechanism. PLoS ONE 9:e111537. https://doi.org/10.1371/journal.pone.0111537
Kim H, Jun S, Kim BS, Kim I-J (2021) Serum Adiponectin in Alzheimer’s Disease (AD): Association with AD Biomarkers and Cognitive Outcome. J Alzheimer’s Dis 84:1163–1172. https://doi.org/10.3233/JAD-210722
Kim MW, Bin Abid N, Jo MH et al (2017) Suppression of adiponectin receptor 1 promotes memory dysfunction and Alzheimer’s disease-like pathologies. Sci Rep 7:12435. https://doi.org/10.1038/s41598-017-12632-9
Kirschner M, Gerhart J (1998) Evolvability. Proc Natl Acad Sci 95:8420–8427. https://doi.org/10.1073/pnas.95.15.8420
Kizer JR, Benkeser D, Arnold AM et al (2012) Associations of Total and High-Molecular-Weight Adiponectin With All-Cause and Cardiovascular Mortality in Older Persons. Circulation 126:2951–2961. https://doi.org/10.1161/CIRCULATIONAHA.112.135202
Kraus M, Greither T, Wenzel C et al (2015) Inhibition of adipogenic differentiation of human SGBS preadipocytes by androgen-regulated microRNA miR-375. Mol Cell Endocrinol 414:177–185. https://doi.org/10.1016/j.mce.2015.07.026
Kubota N, Yano W, Kubota T et al (2007) Adiponectin Stimulates AMP-Activated Protein Kinase in the Hypothalamus and Increases Food Intake. Cell Metab 6:55–68. https://doi.org/10.1016/j.cmet.2007.06.003
Kuljiš RO, Šalković-Petrišić M (2011) Dementia, Diabetes, Alzheimer’s Disease, and Insulin Resistance in the Brain: Progress, Dilemmas, New Opportunities, and a Hypothesis to Tackle Intersecting Epidemics. Journal of Alzheimer’s Disease 25:29–41. https://doi.org/10.3233/JAD-2011-101392
Kulminski AM, He L, Culminskaya I et al (2016) Pleiotropic Associations of Allelic Variants in a 2q22 Region with Risks of Major Human Diseases and Mortality. PLoS Genet 12:e1006314. https://doi.org/10.1371/journal.pgen.1006314
Kusminski CM, McTernan PG, Schraw T et al (2007) Adiponectin complexes in human cerebrospinal fluid: distinct complex distribution from serum. Diabetologia 50:634–642. https://doi.org/10.1007/s00125-006-0577-9
Lahiri D, Maloney B, Riyaz Basha M et al (2007) How and When Environmental Agents and Dietary Factors Affect the Course of Alzheimers Disease: The & #x201C;LEARn” Model (Latent Early-Life Associated Regulation) May Explain the Triggering of AD. Curr Alzheimer Res 4:219–228. https://doi.org/10.2174/156720507780362164
Laping NJ (1999) Therapeutic uses of smad protein inhibitors: Selective inhibition of specific TGF-beta activities. Idrugs 2:907–914
Lau DCW, Dhillon B, Yan H et al (2005) Adipokines: molecular links between obesity and atheroslcerosis. Am J Physiol-Heart Circ Physiol 288:H2031–H2041. https://doi.org/10.1152/ajpheart.01058.2004
Lei L, Zhou C, Yang X, Li L (2018) Down-regulation of microRNA-375 regulates adipokines and inhibits inflammatory cytokines by targeting AdipoR2 in non-alcoholic fatty liver disease. Clin Exp Pharmacol Physiol 45:819–831. https://doi.org/10.1111/1440-1681.12940
Letra L, Matafome P, Rodrigues T et al (2019a) Association between Adipokines and Biomarkers of Alzheimer’s Disease: A Cross-Sectional Study. J Alzheimer’s Dis 67:725–735. https://doi.org/10.3233/JAD-180669
Letra L, Rodrigues T, Matafome P et al (2019b) Adiponectin and sporadic Alzheimer’s disease: Clinical and molecular links. Front Neuroendocrinol 52:1–11. https://doi.org/10.1016/j.yfrne.2017.10.002
Li J, Zhang S (2016) microRNA-150 inhibits the formation of macrophage foam cells through targeting adiponectin receptor 2. Biochem Biophys Res Commun 476:218–224. https://doi.org/10.1016/j.bbrc.2016.05.096
Li L, Hölscher C (2007) Common pathological processes in Alzheimer disease and type 2 diabetes: A review. Brain Res Rev 56:384–402. https://doi.org/10.1016/j.brainresrev.2007.09.001
Li T, Li M, Hu S et al (2017a) MiR-221 mediates the epithelial-mesenchymal transition of hepatocellular carcinoma by targeting AdipoR1. Int J Biol Macromol 103:1054–1061. https://doi.org/10.1016/j.ijbiomac.2017.05.108
Li Y, Cai X, Guan Y et al (2016) Adiponectin Upregulates MiR-133a in Cardiac Hypertrophy through AMPK Activation and Reduced ERK1/2 Phosphorylation. PLoS ONE 11:e0148482. https://doi.org/10.1371/journal.pone.0148482
Li Y, Shan F, Chen J (2017b) Lipid raft-mediated miR-3908 inhibition of migration of breast cancer cell line MCF-7 by regulating the interactions between AdipoR1 and Flotillin-1. World J Surg Oncol 15:69. https://doi.org/10.1186/s12957-017-1120-9
Link AS, Zheng F, Alzheimer C (2016) Activin Signaling in the Pathogenesis and Therapy of Neuropsychiatric Diseases. Front Mol Neurosci 9. https://doi.org/10.3389/fnmol.2016.00032
Liu X, Bai H, Wu X et al (2020) Recombinant adiponectin inhibits the expression of inflammation-associated proteins from mouse astrocytes via AMPK-independent PKC pathway. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi 36:596–602
Liu X, Chen J, Zhang J (2017) AdipoR1-mediated miR-3908 inhibits glioblastoma tumorigenicity through downregulation of STAT2 associated with the AMPK/SIRT1 pathway. Oncol Rep 37:3387–3396. https://doi.org/10.3892/or.2017.5589
Liu Y, Liu F, Grundke-Iqbal I et al (2011) Deficient brain insulin signalling pathway in Alzheimer’s disease and diabetes. J Pathol 225:54–62. https://doi.org/10.1002/path.2912
Lund E, Güttinger S, Calado A et al (1979) (2004) Nuclear Export of MicroRNA Precursors. Science 303:95–98. https://doi.org/10.1126/science.1090599
Lustig Y, Barhod E, Ashwal-Fluss R et al (2014) RNA-Binding Protein PTB and MicroRNA-221 Coregulate AdipoR1 Translation and Adiponectin Signaling. Diabetes 63:433–445. https://doi.org/10.2337/db13-1032
Macesic M, Lalic MN, Kostic SV et al (2017) Impaired Insulin Sensitivity and Secretion in Patients with Alzheimer’s Disease: The Relationship with Other Atherosclerosis Risk Factors. Curr Vasc Pharmacol 15:158–166. https://doi.org/10.2174/1570161114666160905170644
Maddineni S, Metzger S, Ocón O et al (2005) Adiponectin Gene Is Expressed in Multiple Tissues in the Chicken: Food Deprivation Influences Adiponectin Messenger Ribonucleic Acid Expression. Endocrinology 146:4250–4256. https://doi.org/10.1210/en.2005-0254
Meerson A, Traurig M, Ossowski V et al (2013) Human adipose microRNA-221 is upregulated in obesity and affects fat metabolism downstream of leptin and TNF-α. Diabetologia 56:1971–1979. https://doi.org/10.1007/s00125-013-2950-9
Mooldijk SS, Ikram MK, Ikram MA (2021) Adiponectin, Leptin, and Resistin and the Risk of Dementia. J Gerontol: A. https://doi.org/10.1093/gerona/glab267
Ng R, Chan K-H (2017) Potential Neuroprotective Effects of Adiponectin in Alzheimer’s Disease. Int J Mol Sci 18:592. https://doi.org/10.3390/ijms18030592
Ng RC-L, Cheng O-Y, Jian M et al (2016) Chronic adiponectin deficiency leads to Alzheimer’s disease-like cognitive impairments and pathologies through AMPK inactivation and cerebral insulin resistance in aged mice. Mol Neurodegener 11:71. https://doi.org/10.1186/s13024-016-0136-x
Ohara T, Doi Y, Ninomiya T et al (2011) Glucose tolerance status and risk of dementia in the community: The Hisayama Study. Neurology 77:1126–1134. https://doi.org/10.1212/WNL.0b013e31822f0435
Otvos L (2019) Potential Adiponectin Receptor Response Modifier Therapeutics. Front Endocrinol 10. https://doi.org/10.3389/fendo.2019.00539
Pousti F, Ahmadi R, Mirahmadi F et al (2018) Adiponectin modulates synaptic plasticity in hippocampal dentate gyrus. Neurosci Lett 662:227–232. https://doi.org/10.1016/j.neulet.2017.10.042
Pratap AA, Holsinger RMD (2020) Altered Brain Adiponectin Receptor Expression in the 5XFAD Mouse Model of Alzheimer’s Disease. Pharmaceuticals 13:150. https://doi.org/10.3390/ph13070150
Prince M, Bryce R, Albanese E et al (2013) The global prevalence of dementia: A systematic review and metaanalysis. Alzheimer’s Dement 9:63. https://doi.org/10.1016/j.jalz.2012.11.007
Profenno LA, Porsteinsson AP, Faraone SV (2010) Meta-Analysis of Alzheimer’s Disease Risk with Obesity, Diabetes, and Related Disorders. Biol Psychiat 67:505–512. https://doi.org/10.1016/j.biopsych.2009.02.013
Razay G, Wilcock GK (1994) Hyperinsulinaemia and Alzheimer’s Disease. Age Ageing 23:396–399. https://doi.org/10.1093/ageing/23.5.396
Rivera EJ, Goldin A, Fulmer N et al (2005) Insulin and insulin-like growth factor expression and function deteriorate with progression of Alzheimer’s disease: Link to brain reductions in acetylcholine. J Alzheimer’s Dis 8:247–268. https://doi.org/10.3233/JAD-2005-8304
Robertson DM (1991) Transforming growth factor β/inhibin family. Baillière’s Clin Endocrinol Metab 5:615–634. https://doi.org/10.1016/S0950-351X(10)80006-0
Roh JD, Hobson R, Chaudhari V et al (2019) Activin type II receptor signaling in cardiac aging and heart failure. Sci Translat Med 11. https://doi.org/10.1126/scitranslmed.aau8680
Salkovic-Petrisic M, Hoyer S (2007) Central insulin resistance as a trigger for sporadic Alzheimer-like pathology: an experimental approach. In: Neuropsychiatric Disorders An Integrative Approach. Springer Vienna, Vienna, pp 217–233
Scarale MG, Fontana A, Trischitta V et al (2019) Circulating Adiponectin Levels Are Paradoxically Associated With Mortality Rate: A Systematic Review and Meta-Analysis. J Clin Endocrinol Metab 104:1357–1368. https://doi.org/10.1210/jc.2018-01501
Shibata R, Ouchi N, Murohara T (2009) Adiponectin and Cardiovascular Disease. Circ J 73:608–614. https://doi.org/10.1253/circj.CJ-09-0057
Sperling R, Mormino E, Johnson K (2014) The Evolution of Preclinical Alzheimer’s Disease: Implications for Prevention Trials. Neuron 84:608–622. https://doi.org/10.1016/j.neuron.2014.10.038
Stelzmann RA, Norman Schnitzlein H, Reed Murtagh F (1995) An english translation of alzheimer’s 1907 paper, “Uber eine eigenartige erkankung der hirnrinde.” Clin Anat 8:429–431. https://doi.org/10.1002/ca.980080612
Subedi A, Park P-H (2013) Autocrine and paracrine modulation of microRNA-155 expression by globular adiponectin in RAW 264.7 macrophages: Involvement of MAPK/NF-κB pathway. Cytokine 64:638–641. https://doi.org/10.1016/j.cyto.2013.09.011
Takamatsu Y, Ho G, Waragai M et al (2019) Transgenerational Interaction of Alzheimer’s Disease with Schizophrenia through Amyloid Evolvability. J Alzheimer’s Dis 68:473–481. https://doi.org/10.3233/JAD-180986
Talbot K (2014) Brain insulin resistance in Alzheimer’s disease and its potential treatment with GLP-1 analogs. Neurodegener Dis Manag 4:31–40. https://doi.org/10.2217/nmt.13.73
Talbot K, Han L, Schneider JA, et al (2006) O3–02–02: Expression of pIRS–1 (S312 and S616) is elevated in MCI and AD and correlates with cognitive impairment and neurofibrillary pathology. Alzheimer’s Dement 2.https://doi.org/10.1016/j.jalz.2006.05.197
Talbot K, Wang H-Y, Kazi H et al (2012) Demonstrated brain insulin resistance in Alzheimer’s disease patients is associated with IGF-1 resistance, IRS-1 dysregulation, and cognitive decline. J Clin Investig 122:1316–1338. https://doi.org/10.1172/JCI59903
Tsuboi A, Watanabe M, Kazumi T, Fukuo K (2013) Association of Low Serum Iron Levels with Low-grade Inflammation and Hyperadiponectinemia in Community-living Elderly Women. J Atheroscler Thromb 20:670–677. https://doi.org/10.5551/jat.16071
Tsuchida K (2008) Myostatin inhibition by a follistatin-derived peptide ameliorates the pathophysiology of muscular dystrophy model mice. Acta Myol 27:14–18
Ueno N, Nishimatsu S, Murakami K (1990) Activin as a cell differentiation factor. Prog Growth Factor Res 2:113–124. https://doi.org/10.1016/0955-2235(90)90027-H
Uetani E, Tabara Y, Kawamoto R et al (2014) CDH13 Genotype-Dependent Association of High-Molecular Weight Adiponectin With All-Cause Mortality: The J-SHIPP Study. Diabetes Care 37:396–401. https://doi.org/10.2337/dc13-1658
Une K, Takei YA, Tomita N et al (2011) Adiponectin in plasma and cerebrospinal fluid in MCI and Alzheimer’s disease. Eur J Neurol 18:1006–1009. https://doi.org/10.1111/j.1468-1331.2010.03194.x
Unnikrishnan R, Pradeepa R, Joshi SR, Mohan V (2017) Type 2 Diabetes: Demystifying the Global Epidemic. Diabetes 66:1432–1442. https://doi.org/10.2337/db16-0766
Vale W, Rivier J, Vaughan J et al (1986) Purification and characterization of an FSH releasing protein from porcine ovarian follicular fluid. Nature 321:776–779. https://doi.org/10.1038/321776a0
Wan Z, Mah D, Simtchouk S et al (2014) Globular adiponectin induces a pro-inflammatory response in human astrocytic cells. Biochem Biophys Res Commun 446:37–42. https://doi.org/10.1016/j.bbrc.2014.02.077
Wang H, Jiang L, Li Z, et al (2018a) miR-6835-3p regulates the function of pancreatic islet cells by modulating the expression of AdipoR1. Int J Molec Med.https://doi.org/10.3892/ijmm.2018a.3731
Wang X, Li J, Tang W et al (2018b) Adiponectin receptor 1-mediated micro RNA-323-3p regulates functions of the MIN6 cell line via the AMP-activated protein kinase/sirtuin-1 pathway. J Int Med Res 46:1693–1708. https://doi.org/10.1177/0300060518758584
Wanninger J, Neumeier M, Hellerbrand C, et al (2011) Lipid accumulation impairs adiponectin-mediated induction of activin A by increasing TGFbeta in primary human hepatocytes. Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids 1811:626–633. https://doi.org/10.1016/j.bbalip.2010.11.001
Waragai M, Adame A, Trinh I et al (2016) Possible Involvement of Adiponectin, the Anti-Diabetes Molecule, in the Pathogenesis of Alzheimer’s Disease. J Alzheimer’s Dis 52:1453–1459. https://doi.org/10.3233/JAD-151116
Waragai M, Ho G, Takamatsu Y, et al (2020a) Adiponectin Paradox in Alzheimer’s Disease; Relevance to Amyloidogenic Evolvability? Front Endocrinol 11.https://doi.org/10.3389/fendo.2020a.00108
Waragai M, Ho G, Takamatsu Y et al (2018) Dual-therapy strategy for modification of adiponectin receptor signaling in aging-associated chronic diseases. Drug Discov Today 23:1305–1311. https://doi.org/10.1016/j.drudis.2018.05.009
Waragai M, Ho G, Takamatsu Y et al (2020b) Adiponectin Paradox as a Therapeutic Target in Alzheimer’s Disease. J Alzheimer’s Dis 76:1249–1253. https://doi.org/10.3233/JAD-200416
Wei G, Yi S, Yong D et al (2018) miR-320 mediates diabetes amelioration after duodenal-jejunal bypass via targeting adipoR1. Surg Obes Relat Dis 14:960–971. https://doi.org/10.1016/j.soard.2018.03.007
Weigert J, Neumeier M, Wanninger J et al (2009) Adiponectin upregulates monocytic activin A but systemic levels are not altered in obesity or type 2 diabetes. Cytokine 45:86–91. https://doi.org/10.1016/j.cyto.2008.10.017
Wennberg AMV, Gustafson D, Hagen CE et al (2016) Serum Adiponectin Levels, Neuroimaging, and Cognition in the Mayo Clinic Study of Aging. J Alzheimer’s Dis 53:573–581. https://doi.org/10.3233/JAD-151201
Wickner RB (2016) Yeast and Fungal Prions. Cold Spring Harb Perspect Biol 8:a023531. https://doi.org/10.1101/cshperspect.a023531
Wijayarathna R, de Kretser DM (2016) Activins in reproductive biology and beyond. Hum Reprod Update 22:342–357. https://doi.org/10.1093/humupd/dmv058
Williams GC (1957) Pleiotropy, natural selection, and the evolution of senescence. Evolution (N Y) 11:398–411
World Alzheimer Report World Alzheimer Report 2017: The Global Impact of Dementia. http://www.alz.co.uk/research/world-report-2017. Accessed on April 05, 2021
Wu X, Luo J, Liu H et al (2020) Recombinant Adiponectin Peptide Ameliorates Brain Injury Following Intracerebral Hemorrhage by Suppressing Astrocyte-Derived Inflammation via the Inhibition of Drp1-Mediated Mitochondrial Fission. Transl Stroke Res 11:924–939. https://doi.org/10.1007/s12975-019-00768-x
Zhang D, Wang X, Lu X-Y (2016) Adiponectin Exerts Neurotrophic Effects on Dendritic Arborization, Spinogenesis, and Neurogenesis of the Dentate Gyrus of Male Mice. Endocrinology 157:2853–2869. https://doi.org/10.1210/en.2015-2078
Zhao C, Deng W, Gage FH (2008) Mechanisms and Functional Implications of Adult Neurogenesis. Cell 132:645–660. https://doi.org/10.1016/j.cell.2008.01.033
Funding
This study was supported by the following Brazilian agencies: 1. Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES).
Author information
Authors and Affiliations
Contributions
Authors contributed equally to the manuscript. The illustrations were designed by Rômulo Sperduto Dezonne. We thank Miss Janet Reid for English review of the manuscript.
Corresponding author
Ethics declarations
Competing of interest
The authors declare that they have no financial interests. The research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Ethics approval
Not applicable.
Consent to participate
Not applicable.
Consent to publish
Not applicable.
Additional information
Publisher's note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
Springer Nature or its licensor holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
About this article
Cite this article
Dezonne, R.S., Pereira, C.M., de Moraes Martins, C.J. et al. Adiponectin, the adiponectin paradox, and Alzheimer’s Disease: Is this association biologically plausible?. Metab Brain Dis 38, 109–121 (2023). https://doi.org/10.1007/s11011-022-01064-8
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11011-022-01064-8